On the stock market since 2021, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 60% below its peak. The market has trimmed its expectations for the company.
Sales run at $87.1M a year. A small number, but proof the product has real buyers.
A loss of $8.0M against $87.1M in annual sales.
The stock sits at $0.30. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 12 months, executives reported 6 sells against just 0 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, VENAR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VENAR is a high-risk stock — not yet profitable, and its future rides on its product catching on.